Valuation: Poxel

Market Cap 1.26Cr 1.44Cr 1.19Cr 1.08Cr 2.02Cr 138.35Cr 2.03Cr 14Cr 5.49Cr 70Cr 5.42Cr 5.3Cr 226.33Cr P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 7.97Cr 9.13Cr 7.52Cr 6.83Cr 13Cr 876.52Cr 13Cr 90Cr 35Cr 445.64Cr 34Cr 34Cr 1.43TCr EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+0.87%
1 week-9.65%
Current month-18.91%
1 month-16.24%
3 months-18.50%
6 months-34.80%
Current year-30.34%
1 week 0.16
Extreme 0.158
0.18
1 month 0.16
Extreme 0.158
0.25
Current year 0.16
Extreme 0.158
0.48
1 year 0.16
Extreme 0.158
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.42
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member 59 31/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
04/02/22 Exercice

Founder

67,000 0.2334%
04/02/22 Exercice

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+0.87%-9.65%-45.12%-68.23% 99.69L
-0.31%+5.79%+48.93%+97.53% 7.09TCr
+0.39%+2.06%+40.91%+78.49% 6.23TCr
-3.21%-7.27%-17.73%+351.98% 2.71TCr
+0.50%+7.13%+29.43%+15.48% 2.62TCr
-2.64%-0.69%-0.26%-11.90% 2.48TCr
+0.71%+8.03%+27.22%-13.18% 2.06TCr
-1.26%-7.81%+169.33%+302.38% 1.55TCr
-0.22%+3.99%+44.28%+173.35% 1.45TCr
+0.73%+1.71%-7.18%+886.19% 1.41TCr
Average -0.44%+0.63%+28.98%+181.21% 2.76TCr
Weighted average by Cap. -0.49%+1.49%+36.34%+148.20%

Financials

2023 2024
Net sales 19.81L 22.72L 18.71L 16.99L 31.82L 22Cr 31.96L 2.24Cr 86.46L 11Cr 85.34L 83.45L 36Cr 66.36L 76.1L 62.66L 56.9L 1.07Cr 73Cr 1.07Cr 7.51Cr 2.9Cr 37Cr 2.86Cr 2.8Cr 119.46Cr
Net income -3.51Cr -4.02Cr -3.31Cr -3.01Cr -5.64Cr -386.13Cr -5.66Cr -40Cr -15Cr -196.31Cr -15Cr -15Cr -631.66Cr -1.83Cr -2.1Cr -1.73Cr -1.57Cr -2.94Cr -201.43Cr -2.95Cr -21Cr -7.99Cr -102.41Cr -7.89Cr -7.71Cr -329.51Cr
Net Debt 4.64Cr 5.32Cr 4.38Cr 3.98Cr 7.46Cr 510.84Cr 7.49Cr 53Cr 20Cr 259.72Cr 20Cr 20Cr 835.67Cr 6.71Cr 7.69Cr 6.33Cr 5.75Cr 11Cr 738.17Cr 11Cr 76Cr 29Cr 375.3Cr 29Cr 28Cr 1.21TCr
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
18/26/18 €0.1630 +0.87% 1,36,146
17/26/17 €0.1616 -3.81% 3,61,596
16/26/16 €0.1680 -5.62% 3,36,659
15/26/15 €0.1780 +0.11% 93,706
14/26/14 €0.1778 -1.44% 2,60,035
  1. Stock Market
  2. Stocks
  3. POXEL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!